Equities

Aclaris Therapeutics Inc

Aclaris Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.56
  • Today's Change-0.07 / -2.66%
  • Shares traded628.50k
  • 1 Year change-46.16%
  • Beta0.2287
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.

  • Revenue in USD (TTM)27.08m
  • Net income in USD-37.00m
  • Incorporated2012
  • Employees91.00
  • Location
    Aclaris Therapeutics Inc701 Lee Road, Suite 103WAYNE 19087United StatesUSA
  • Phone+1 (484) 324-7933
  • Fax+1 (302) 655-5049
  • Websitehttps://www.aclaristx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Actuate Therapeutics Inc-100.00bn-100.00bn175.20m11.00---------------1.05-------------------------------------22.74------
Cardiff Oncology Inc689.00k-43.01m176.92m31.00--3.41--256.78-0.9493-0.94930.01521.010.0091--1.6922,225.81-56.80-31.24-66.22-33.56-----6,238.17-7,819.23----0.00--26.425.22-7.07--157.91--
Lineage Cell Therapeutics Inc6.19m-24.19m178.26m75.00--2.61--28.82-0.1342-0.13420.03430.36170.0577--18.2582,480.00-22.57-19.53-26.03-22.5990.8389.13-391.25-370.88----0.0017---39.1612.3918.22---27.16--
Galectin Therapeutics Inc0.00-48.03m179.98m14.00---------0.7831-0.78310.00-1.320.00----0.00-185.54-92.08-382.33-121.97-----------8.598.29-------15.26------
DiaMedica Therapeutics Inc0.00-19.90m180.82m18.00--3.38-----0.5238-0.52380.001.250.00----0.00-33.49-45.38-34.98-48.24------------0.0006-------41.72---13.65--
Greenwich Lifesciences Inc0.00-10.22m184.81m3.00--31.27-----0.7942-0.79420.000.44960.00----0.00-112.41-36.43-123.67-38.31------------0.00-------13.63------
Aclaris Therapeutics Inc27.08m-37.00m187.86m91.00--1.44--6.94-0.5198-0.51980.38061.820.1352--78.61297,582.40-18.47-47.29-20.87-53.8753.5344.00-136.65-549.18----0.00--5.0338.41-1.81---0.703--
Sagimet Biosciences Inc2.00m-29.25m188.34m10.00--1.02--94.17-1.18-1.180.0785.740.019----200,000.00-27.79---29.32-------1,462.55------0.00------8.60------
Inhibikase Therapeutics Inc79.57k-18.38m188.77m8.00--4.06--2,372.40-2.93-2.930.01260.70630.0051----9,946.25-117.93-66.49-148.63-85.55-----23,102.16-1,139.14----0.00--111.03-42.21-5.40------
Black Diamond Therapeutics Inc0.00-73.10m191.26m54.00--1.96-----1.36-1.360.001.720.00----0.00-47.12-40.29-53.28-43.29------------0.00------9.57---15.37--
Acumen Pharmaceuticals Inc0.00-64.86m193.46m51.00--0.793-----1.11-1.110.004.060.00----0.00-27.82---29.32--------------0.1075-------22.20------
Gossamer Bio Inc105.32m-71.65m194.15m135.00--3.59--1.84-0.3283-0.32830.45950.23890.3014----780,162.90-20.51-57.43-23.67-64.38-----68.03-----6.840.7847------21.61------
Verastem Inc10.00m-93.45m198.50m73.00--16.24--19.85-3.18-3.180.33110.80020.0661--100.00136,986.30-61.78-62.70-77.44-75.18-----934.54-406.17----0.5579---100.00---18.36------
Tenaya Therapeutics Inc0.00-117.23m203.60m140.00--1.81-----1.44-1.440.001.420.00----0.00-70.20---78.56--------------0.00-------0.3388------
Atossa Therapeutics Inc0.00-25.91m203.73m10.00--2.54-----0.2064-0.20640.000.63740.00----0.00-26.68-29.97-28.00-32.55------------0.00-------11.62---33.90--
Data as of Nov 12 2024. Currency figures normalised to Aclaris Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

52.00%Per cent of shares held by top holders
HolderShares% Held
BML Capital Management LLCas of 30 Sep 202414.25m19.97%
The Vanguard Group, Inc.as of 30 Jun 20244.67m6.54%
D. E. Shaw & Co. LPas of 30 Jun 20243.32m4.65%
Millennium Management LLCas of 30 Sep 20243.01m4.21%
Rock Springs Capital Management LPas of 30 Jun 20242.75m3.86%
Stonepine Capital Management LLCas of 30 Jun 20241.93m2.70%
Acadian Asset Management LLCas of 30 Jun 20241.91m2.68%
Trium Capital LLPas of 30 Sep 20241.91m2.68%
BlackRock Fund Advisorsas of 30 Jun 20241.91m2.68%
Two Sigma Advisers LPas of 30 Jun 20241.44m2.01%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.